{"id":993803,"date":"2026-08-11T16:38:21","date_gmt":"2026-08-11T20:38:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-reports-second-quarter-2026-results-and-provides-business-update\/"},"modified":"2026-08-11T16:38:21","modified_gmt":"2026-08-11T20:38:21","slug":"cardiff-oncology-reports-second-quarter-2026-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-reports-second-quarter-2026-results-and-provides-business-update\/","title":{"rendered":"Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update"},"content":{"rendered":"
\n

\n Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI\/bevacizumab into planned registrational program for first-line RAS-mutated mCRC<\/em>\n <\/p>\n

\n Following successful End-of-Phase 2 meeting with FDA, Company aligned on key elements of registrational trial; plans to initiate study in Q1 2027, subject to securing additional financing<\/em>\n <\/p>\n

\n Completed $10 million Registered Direct offering, extending cash runway <\/em>\n <\/p>\n

SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.<\/p>\n

\u201cThe second quarter was an important period of progress for Cardiff, highlighted by the presentation of positive Phase 2 data at ASCO and our continued progress in preparation for a planned registrational trial of onvansertib in first-line RAS-mutated metastatic colorectal cancer,\u201d said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. \u201cThe updated CRDF-004 results reinforced our confidence in the selected registrational dose and regimen of 30 mg onvansertib in combination with FOLFIRI\/bevacizumab. This regimen has demonstrated deep and durable tumor shrinkage over time, reflecting the synergistic mechanisms of action, while maintaining a well-tolerated safety profile with no overlapping or new toxicities when added to standard-of-care therapy.\u201d<\/p>\n

Dr. Mohindru continued, \u201cFollowing our successful End-of-Phase 2 meeting with the FDA, we are preparing to initiate the planned Phase 3 trial in the first quarter of 2027, subject to securing additional financing. We believe the totality of data generated to date strengthens onvansertib\u2019s potential to become an important new treatment option for patients with first-line RAS-mutated metastatic colorectal cancer, an area where there remains significant unmet need.\u201d<\/p>\n

\n
\n Clinical and Regulatory Highlights<\/u>
\n <\/strong>\n <\/p>\n

\n Presented Positive Results from Randomized, Controlled Phase 2 CRDF-004 Trial at the 2026 American Society of Clinical Oncology (\u201cASCO\u201d) Annual Meeting<\/strong>\n <\/p>\n

In June, Cardiff presented positive results from CRDF-004, its ongoing, randomized, controlled, dose-finding Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (\u201cSoC\u201d) regimens in patients with first-line RAS-mutated metastatic colorectal cancer (\u201cmCRC\u201d), in a rapid oral presentation at the 2026 ASCO Annual Meeting.<\/p>\n

The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib plus SoC regimen for the registrational program. The selected regimen, 30 mg onvansertib in combination with FOLFIRI\/bevacizumab (\u201cbev\u201d), demonstrated deep and durable tumor shrinkage, including clinically meaningful improvements in confirmed objective response rate (\u201cORR\u201d) and progression-free survival (\u201cPFS\u201d) compared to SoC alone, with no additive adverse events observed. Data highlights from the ongoing Phase 2 trial, based on a March 18, 2026 data cut, are listed below, with the full press release available here<\/a>:<\/p>\n